Omzet 2024 * | 120 mln. 110 mln. | Omzet 2025 * | 130 mln. 120 mln. | Marktkapitalisatie | 98,93 mln. 91,04 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -16 mln. -14,72 mln. | Nettowinst (verlies) 2025 * | 1 mln. 920K | EV/omzet 2024 * | 0,82 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 0,76 x |
K/w-verhouding 2024 * |
-6,12
x | K/w-verhouding 2025 * |
208
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,83% |
Recentste transcriptie over Depomed Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Heather Mason
CEO | Chief Executive Officer | 63 | 01-02-19 |
Ajay Patel
DFI | Director of Finance/CFO | 40 | 01-07-19 |
Howard Franklin
CTO | Chief Tech/Sci/R&D Officer | - | 06-03-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Peter Staple
CHM | Chairman | 72 | 01-11-03 |
James Tyree
BRD | Director/Board Member | 71 | 01-10-16 |
William McKee
BRD | Director/Board Member | 62 | 01-03-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+34,35% | 705 mld. | |
+30,71% | 583 mld. | |
-3,49% | 364 mld. | |
+20,15% | 332 mld. | |
+6,19% | 291 mld. | |
+15,66% | 238 mld. | |
-3,48% | 210 mld. | |
+10,37% | 209 mld. | |
+9,21% | 169 mld. |